Related Experiment Videos
Langerhans cell histiocytosis in children under 2 years of age
R Rivera-Luna1, N Alter-Molchadsky, R Cardenas-Cardos
1Department of Oncology, Instituto Nacional de Pediatría, Delegación Coyoacán México, D.F. Mexico.
Insights
Langerhans cell histiocytosis (LCH) in young children is often fatal if organ dysfunction is present. Infants under 6 months with LCH face an 81.3% fatality rate, highlighting critical risk factors.
Area of Science:
- Pediatric Oncology
- Hematology
- Immunology
Background:
- Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disease affecting children.
- Early diagnosis and risk stratification are crucial for managing LCH outcomes.
- Lahey's criteria provide a framework for assessing organ involvement and dysfunction in LCH.
Purpose of the Study:
- To analyze the impact of age and organ dysfunction on the outcomes of pediatric LCH.
- To identify specific clinical factors associated with mortality in infants and young children with LCH.
- To evaluate the long-term sequelae of LCH treatment in survivors.
Main Methods:
- Retrospective analysis of 55 pediatric patients diagnosed with LCH under 2 years of age.
- Classification based on age at diagnosis (0-6, 7-12, 13-18, 19-24 months) and organ function using Lahey's criteria.
- Statistical analysis to determine the significance of age, organ dysfunction, thrombocytopenia, and respiratory dysfunction on patient outcomes.
Main Results:
- No significant difference in outcome was observed across different age groups, but the fatality rate was 81.3% in infants under 6 months.
- Organ dysfunction was a statistically significant predictor of mortality (P > 0.005).
- Thrombocytopenia and/or respiratory dysfunction were strongly associated with fatal outcomes. No second malignancies were reported in survivors, but late effects included endocrine, orofacial, and osseous pathologies.
Conclusions:
- Organ dysfunction is a critical determinant of mortality in pediatric LCH, particularly in infants.
- Early identification of thrombocytopenia and respiratory compromise is vital for improving survival rates in LCH.
- Long-term monitoring for treatment-related sequelae is essential in pediatric LCH survivors.
Abstract:
This is a retrospective study of 55 children under the age of 2 years diagnosed with Langerhans cell histiocytosis (LCH). They were classified according to age and organ function and dysfunction following Lahey's criteria. The studied population was divided into four groups by age of diagnosis (0-6, 7-12, 13-18, and 19-24 months). Statistical analysis showed no significant difference in outcome between age groups, although the population under 6 months had a 81.3% fatality rate. The presence of organ dysfunction was a major cause of death in all age groups, being statistically significant in outcome (P > 0.005) compared with patients without organ dysfunction. The presence of thrombocytopenia and/or respiratory dysfunction was also highly associated with a fatal outcome. In the surviving population, no second malignancies have been reported. The late secondary effects of therapy include endocrine, orofacial, and osseous pathologies.